老年性黃斑部退化是造成65 歲以上失明的主要原因。血管內皮生長因子已被認為在 形成新生血管過程中扮演重要角色，包括見於濕性老年性黃斑部退化的脈絡膜新生血管。 拮抗血管內皮生長因子的活性是目前濕性老年性黃斑部退化的黃金標準治療法。除了研發 更有效率及更長療效的抗血管內皮生長因子藥物，其他相關具有潛力的療法也在研究中。 此篇綜論探及目前使用及近來受矚目治療老年性黃斑部退化的抗血管內皮生長因子藥物。

Age-related macular degeneration (AMD) is the major cause of visual loss for people over the age of 65. Vascular endothelial growth factor (VEGF) has been recognized to have a critical role in angiogenesis cascade, including choroidal neovascuarization in wet AMD. Neutralization of VEGF activity is currently the gold standard treatment of wet AMD. In addition to developing new anti-VEGF agents with better efficiency and longer durability, researches on other related potential approaches are undergoing. This article reviews the available as well as the promising therapeutic agents engineered to inhibit the angiogenic pathway for the treatment of wet AMD.